Lymphoma by Site — Trials

Lymphoma by Site — Trials · CancerIndex

Clinical trials

Registered studies

900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 250
Recruiting: 134
Ph III recruiting: 7
Growth YoY: +20%
Industry share: 17%
Top sponsor: National Cancer Institute (NCI)
Termination share: 33.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (130)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05728879	Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution	not yet recruiting	Early Phase 1	30	Northwestern UniversityOTHER	1	May 1, 2026	clinicaltrials
NCT07213882	A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)(CITY)	not yet recruiting	Early Phase 1	30	Assistance Publique - Hôpitaux de Paris